Mark R. Waddle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark R. Waddle has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
Federico Mastroleo
7 shared publications- Satomi Shiraishi
Department of Radiation Oncology, Mayo Clinic, Rochester, USA
5 shared publications - David M. Routman
Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
4 shared publications - Mariana Borras-Osorio
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States
4 shared publications - Robert C. Miller
Mayo Clinic, Emeritus Office
4 shared publications Satomi Shiraishi
4 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in Advances in Radiation Oncology
PRECISE-PC: Prompt-driven Retrieval and Extraction of Clinical Information with Structured Evaluation for Prostate Cancer
- 20 October 2026
- Published by Elsevier in Advances in Radiation Oncology
Open AccessPRECISE-PC: Prompt-driven Retrieval and Extraction of Clinical Information with Structured Evaluation for Prostate Cancer
- Open Access
- 10 October 2026
- Published by Springer Nature in npj Digital Medicine
VOICE-AE: automated CTCAE scoring from ambient clinical audio using speech recognition and large language models
Treatment-related adverse event documentation is labor-intensive and subject to inter-observer variability. We developed and evaluated VOICE-AE, a multi-stage pipeline integrating automatic speech recognition, speaker diarization and large language models (LLMs) for automated extraction and grading of Common Terminology Criteria for Adverse Events (CTCAE) toxicities from clinician-patient audio recordings. Encounters of prostate cancer patients undergoing radiotherapy were recorded and processed through VOICE-AE. Six blinded human raters independently graded 10 genitourinary/gastrointestinal toxicities from the same transcripts; hierarchical clustering identified an expert-rater subgroup that established the consensus reference standard. A total of 31 patients (39 encounters) were enrolled, yielding 390 encounter–toxicity assessments, of which 300 (76.9%) carried a reference grade of 0. Six-rater Krippendorff alpha was 0.677 for ordinal grading. Against reference standard, VOICE-AE achieved a mean weighted kappa of 0.717 and Krippendorff alpha of 0.669. Exact CTCAE grade match was 82.6% and within-one-grade accuracy 99.2%; because grade 0 predominated, a trivial classifier always predicting grade 0 would achieve 76.9% and 93.6% respectively. Performance was weaker at the grades that drive clinical action (grade 1 F1 0.58; grade 2 F1 0.57), and binary detection sensitivity was 77.8% with specificity 89.0% and precision 68.0%. In a like-for-like comparison restricted to the three expert-cluster raters, mean weighted kappa between VOICE-AE and those experts (0.666) fell just below agreement among the experts themselves (0.681). VOICE-AE performed within the range of inter-expert agreement, supporting the feasibility of automated, post-encounter AE documentation. Accuracy at grade ≥2 and detection of severe toxicity remain unproven.
- 10 October 2026
- Published by Springer Nature in npj Digital Medicine
Open AccessVOICE-AE: automated CTCAE scoring from ambient clinical audio using speech recognition and large language models
Treatment-related adverse event documentation is labor-intensive and subject to inter-observer variability. We developed and evaluated VOICE-AE, a multi-stage pipeline integrating automatic speech recognition, speaker diarization and large language models (LLMs) for automated extraction and grading of Common Terminology Criteria for Adverse Events (CTCAE) toxicities from clinician-patient audio recordings. Encounters of prostate cancer patients undergoing radiotherapy were recorded and processed through VOICE-AE. Six blinded human raters independently graded 10 genitourinary/gastrointestinal toxicities from the same transcripts; hierarchical clustering identified an expert-rater subgroup that established the consensus reference standard. A total of 31 patients (39 encounters) were enrolled, yielding 390 encounter–toxicity assessments, of which 300 (76.9%) carried a reference grade of 0. Six-rater Krippendorff alpha was 0.677 for ordinal grading. Against reference standard, VOICE-AE achieved a mean weighted kappa of 0.717 and Krippendorff alpha of 0.669. Exact CTCAE grade match was 82.6% and within-one-grade accuracy 99.2%; because grade 0 predominated, a trivial classifier always predicting grade 0 would achieve 76.9% and 93.6% respectively. Performance was weaker at the grades that drive clinical action (grade 1 F1 0.58; grade 2 F1 0.57), and binary detection sensitivity was 77.8% with specificity 89.0% and precision 68.0%. In a like-for-like comparison restricted to the three expert-cluster raters, mean weighted kappa between VOICE-AE and those experts (0.666) fell just below agreement among the experts themselves (0.681). VOICE-AE performed within the range of inter-expert agreement, supporting the feasibility of automated, post-encounter AE documentation. Accuracy at grade ≥2 and detection of severe toxicity remain unproven.
- Open Access
- 9 September 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (5) , ooaf172
Patient-reported outcomes in radiotherapy (PRO-RT) utilizing an integrated patient portal; results from a prospective single-arm trial
Objectives: This prospective single-arm trial assessed the use of an integrated patient platform (IPP) and effects on patient-reported outcomes survey (PROs) completion. Materials and Methods: Head and neck, breast, and thoracic cancer patients undergoing radiotherapy (RT) were approached for registration for an IPP for PRO administration and integration of multiple health portals. Results: Seventy-two patients were approached, 27 (38%) enrolled, and 18 used the IPP for PROs, 2 of which utilized integrative features. IPP user PRO completion rates were 100%, 89%, 89%, and 94% at baseline, end of RT, and 3- and 6-months post-RT, higher than the standard interface. Of the 45 who declined, 24 (53%) reported information security concerns. Discussion: While the IPP increased PRO completion, many declined enrollment, citing security concerns. Few utilized the portal’s integrative features. Conclusion: IPPs show promise in aiding PRO completion; continued efforts to demonstrate data safety and utility of IPPs are merited.
- 9 September 2026
- Published by Oxford University Press (OUP) in JAMIA Open
- Vol. 9 (5) , ooaf172
Open AccessPatient-reported outcomes in radiotherapy (PRO-RT) utilizing an integrated patient portal; results from a prospective single-arm trial
Objectives: This prospective single-arm trial assessed the use of an integrated patient platform (IPP) and effects on patient-reported outcomes survey (PROs) completion. Materials and Methods: Head and neck, breast, and thoracic cancer patients undergoing radiotherapy (RT) were approached for registration for an IPP for PRO administration and integration of multiple health portals. Results: Seventy-two patients were approached, 27 (38%) enrolled, and 18 used the IPP for PROs, 2 of which utilized integrative features. IPP user PRO completion rates were 100%, 89%, 89%, and 94% at baseline, end of RT, and 3- and 6-months post-RT, higher than the standard interface. Of the 45 who declined, 24 (53%) reported information security concerns. Discussion: While the IPP increased PRO completion, many declined enrollment, citing security concerns. Few utilized the portal’s integrative features. Conclusion: IPPs show promise in aiding PRO completion; continued efforts to demonstrate data safety and utility of IPPs are merited.
- 3 September 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (2) , 290
Trust but Verify: Smell Tests Across the Clinical Artificial Intelligence Landscape
- 3 September 2026
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 126 (2) , 290
Trust but Verify: Smell Tests Across the Clinical Artificial Intelligence Landscape
- Open Access
- 18 June 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Translational barriers to digital twins in radiation oncology
- 18 June 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 40
Open AccessTranslational barriers to digital twins in radiation oncology
Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma
Background: Vorasidenib is Food and Drug Administration‐approved for treatment of grade 2 isocitrate dehydrogenase (IDH)–mutant gliomas and has demonstrated a benefit in progression‐free survival compared to a placebo. This study assessed the cost‐effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT). Methods: The authors used an integrated Markov model to compare quality‐adjusted life‐years (QALY) gained and cost‐effectiveness of patients with IDH‐mutated low‐grade glioma (LGG) treated with vorasidenib, observation, or CRT. Outcomes were expressed as incremental cost‐effectiveness ratios (ICERs) per QALY gained. Treatment is considered cost‐effective if it meets the commonly accepted willingness‐to‐pay threshold of $100,000 per QALY gained. Results: Based on model parameters, vorasidenib demonstrated an ICER of $356,756 per QALY when compared to CRT. When compared to observation, vorasidenib demonstrated an improved ICER of $215,191 per QALY. On one‐way sensitivity analysis compared to observation, median cost of vorasidenib and median overall survival were most likely to affect ICER with only marginal changes on analysis of other model factors. For ICER to become ≤$100,000 compared to observation, the cost of vorasidenib would need to drop to below $14,072 monthly or have a median survival gain of at least 11.9 years. The probabilistic sensitivity analysis demonstrated that vorasidenib was favored in none of 5000 Monte Carlo iterations. Conclusion: Using the best available data, the current price of vorasidenib does not meet commonly accepted cost‐effectiveness thresholds in treatment of IDH‐mutated LGGs.
Cost‐effectiveness of vorasidenib in treatment of isocitrate dehydrogenase–mutated low‐grade glioma
Background: Vorasidenib is Food and Drug Administration‐approved for treatment of grade 2 isocitrate dehydrogenase (IDH)–mutant gliomas and has demonstrated a benefit in progression‐free survival compared to a placebo. This study assessed the cost‐effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT). Methods: The authors used an integrated Markov model to compare quality‐adjusted life‐years (QALY) gained and cost‐effectiveness of patients with IDH‐mutated low‐grade glioma (LGG) treated with vorasidenib, observation, or CRT. Outcomes were expressed as incremental cost‐effectiveness ratios (ICERs) per QALY gained. Treatment is considered cost‐effective if it meets the commonly accepted willingness‐to‐pay threshold of $100,000 per QALY gained. Results: Based on model parameters, vorasidenib demonstrated an ICER of $356,756 per QALY when compared to CRT. When compared to observation, vorasidenib demonstrated an improved ICER of $215,191 per QALY. On one‐way sensitivity analysis compared to observation, median cost of vorasidenib and median overall survival were most likely to affect ICER with only marginal changes on analysis of other model factors. For ICER to become ≤$100,000 compared to observation, the cost of vorasidenib would need to drop to below $14,072 monthly or have a median survival gain of at least 11.9 years. The probabilistic sensitivity analysis demonstrated that vorasidenib was favored in none of 5000 Monte Carlo iterations. Conclusion: Using the best available data, the current price of vorasidenib does not meet commonly accepted cost‐effectiveness thresholds in treatment of IDH‐mutated LGGs.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500167
Large Language Model and Natural Language Processing Approach to Identify Cancer Recurrence From Pathology Reports
PURPOSE: Cancer recurrence is a critical outcome for patients and physicians. Retrospective cancer recurrence data can evaluate recurrence-directed treatment and generate novel interventions targeting recurrent cancers. However, large cancer databases do not provide recurrence-related information, stymying study at scale, and consequently require significant manual record review. Automated evaluation of records may allow for the rapid generation of easily analyzed data sets, accelerating the evaluation of recurrence altogether. METHODS: Patients treated with radiation therapy at one tertiary referral center from 2010 to 2018 with a verified cancer status (cancer recurrence v no cancer recurrence) were identified. Patients with recurrent disease were initially identified through manual record review, and the associated pathology report was collected. Google Automated Machine Learning with Natural Language Processing (AutoNLP) and Google Gemini 1.5 Pro were used to generate a model for binary classification, with comparison to the gold-standard manually developed data set. RESULTS: A total of 7,054 patients were identified. 3,431 (48.6%) were female, with a median age of 64 years. Head and neck (1,482, 21%), breast (1,480, 21%), upper GI (1,307, 18.5%), and lung/thorax (1,107, 15.7%) were the most common disease sites. Recurrence was verified for 1,546 patients (21.9%) using pathology reports, of which 1,249 positive cases were paired with 651 negative pathology reports for model development. Google Gemini 1.5 Pro consistently outperformed AutoNLP across all measurements of accuracy, generating a greater absolute difference in precision, recall, negative predictive value, and specificity, and a higher likelihood of correct classification at the individual level, rendering Gemini superior in recurrence status extraction. CONCLUSION: AutoNLP and Google Gemini 1.5 Pro are promising tools for identifying recurrence from pathology reports, with the latter demonstrating superior overall performance, making it particularly suitable for clinical translation.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500167
Large Language Model and Natural Language Processing Approach to Identify Cancer Recurrence From Pathology Reports
PURPOSE: Cancer recurrence is a critical outcome for patients and physicians. Retrospective cancer recurrence data can evaluate recurrence-directed treatment and generate novel interventions targeting recurrent cancers. However, large cancer databases do not provide recurrence-related information, stymying study at scale, and consequently require significant manual record review. Automated evaluation of records may allow for the rapid generation of easily analyzed data sets, accelerating the evaluation of recurrence altogether. METHODS: Patients treated with radiation therapy at one tertiary referral center from 2010 to 2018 with a verified cancer status (cancer recurrence v no cancer recurrence) were identified. Patients with recurrent disease were initially identified through manual record review, and the associated pathology report was collected. Google Automated Machine Learning with Natural Language Processing (AutoNLP) and Google Gemini 1.5 Pro were used to generate a model for binary classification, with comparison to the gold-standard manually developed data set. RESULTS: A total of 7,054 patients were identified. 3,431 (48.6%) were female, with a median age of 64 years. Head and neck (1,482, 21%), breast (1,480, 21%), upper GI (1,307, 18.5%), and lung/thorax (1,107, 15.7%) were the most common disease sites. Recurrence was verified for 1,546 patients (21.9%) using pathology reports, of which 1,249 positive cases were paired with 651 negative pathology reports for model development. Google Gemini 1.5 Pro consistently outperformed AutoNLP across all measurements of accuracy, generating a greater absolute difference in precision, recall, negative predictive value, and specificity, and a higher likelihood of correct classification at the individual level, rendering Gemini superior in recurrence status extraction. CONCLUSION: AutoNLP and Google Gemini 1.5 Pro are promising tools for identifying recurrence from pathology reports, with the latter demonstrating superior overall performance, making it particularly suitable for clinical translation.
- Open Access
- 19 December 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 37, 100372
From BERT to GPT-4: A systematic review of AI-Driven toxicity extraction and grading in radiation oncology
- 19 December 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 37, 100372
Open AccessFrom BERT to GPT-4: A systematic review of AI-Driven toxicity extraction and grading in radiation oncology
- 18 December 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 216, 111348
Large language models for toxicity extraction in oncology trials: A real-world benchmark in prostate radiotherapy
- 18 December 2025
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 216, 111348
Large language models for toxicity extraction in oncology trials: A real-world benchmark in prostate radiotherapy
- 6 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 691-698
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation
Background: Partial breast irradiation (PBI) is an effective treatment for early-stage breast cancer. However, evidence comparing different PBI modalities is limited. Methods: This trial emulation uses electronic health records from a multi-state large tertiary health system. Three PBI modalities were compared: proton radiation therapy, photon radiation therapy, and applicator-based brachytherapy. Inverse probability weighting (IPW) was used to balance confounders. The primary outcome was ipsilateral breast recurrence (IBR). Results: Between 2013 and 2023, 1041 women with early-stage breast cancer were treated with PBI. Of these, 1026 patients were included in the analyses. The median age was 66 years; 22.51% had ductal carcinoma in situ (DCIS), and 97.56% were estrogen receptor positive. With median follow-up of 38.2 months, the rate of IBR in the overall group was 3.05% (95% confidence interval [CI] = 1.99% to 4.65%) at 3 years. After IPW, compared with photon PBI, the hazard ratio for IBR for proton PBI was 2.11 (95% CI = 0.70 to 6.33) and for brachytherapy, 3.86 (95% CI = 1.39 to 10.69). Compared with proton PBI, the hazard ratio for IBR for brachytherapy was 1.83 (95% CI = 0.88 to 3.81). IBR risk was similar across PBI modalities for patients with tumor size ≤ 10 mm and in patients treated for DCIS. Among patients with tumor size >10 mm, the hazard ratio for IBR for brachytherapy was 7.64 (95% CI = 1.64 to 35.58) and 3.59 (95% CI = 1.22 to 10.56) relative to photons and protons, respectively. Conclusion: PBI with applicator-based brachytherapy was associated with higher IBR than photon or proton PBI in patients with tumor size > 10 mm, suggesting the need for more careful PBI patient selection for this modality.
- 6 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 691-698
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation
Background: Partial breast irradiation (PBI) is an effective treatment for early-stage breast cancer. However, evidence comparing different PBI modalities is limited. Methods: This trial emulation uses electronic health records from a multi-state large tertiary health system. Three PBI modalities were compared: proton radiation therapy, photon radiation therapy, and applicator-based brachytherapy. Inverse probability weighting (IPW) was used to balance confounders. The primary outcome was ipsilateral breast recurrence (IBR). Results: Between 2013 and 2023, 1041 women with early-stage breast cancer were treated with PBI. Of these, 1026 patients were included in the analyses. The median age was 66 years; 22.51% had ductal carcinoma in situ (DCIS), and 97.56% were estrogen receptor positive. With median follow-up of 38.2 months, the rate of IBR in the overall group was 3.05% (95% confidence interval [CI] = 1.99% to 4.65%) at 3 years. After IPW, compared with photon PBI, the hazard ratio for IBR for proton PBI was 2.11 (95% CI = 0.70 to 6.33) and for brachytherapy, 3.86 (95% CI = 1.39 to 10.69). Compared with proton PBI, the hazard ratio for IBR for brachytherapy was 1.83 (95% CI = 0.88 to 3.81). IBR risk was similar across PBI modalities for patients with tumor size ≤ 10 mm and in patients treated for DCIS. Among patients with tumor size >10 mm, the hazard ratio for IBR for brachytherapy was 7.64 (95% CI = 1.64 to 35.58) and 3.59 (95% CI = 1.22 to 10.56) relative to photons and protons, respectively. Conclusion: PBI with applicator-based brachytherapy was associated with higher IBR than photon or proton PBI in patients with tumor size > 10 mm, suggesting the need for more careful PBI patient selection for this modality.